Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension (e-MOTION PH)
19. desember 2017 oppdatert av: Bayer
(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) over 6 months in routine clinical practice settings.
Studieoversikt
Detaljert beskrivelse
Remote patient monitoring can lead to improved patient outcomes, including improved quality of life, reduced readmissions, earlier treatment for symptoms detected prior to schedule in-office follow-up visits, improved communications with care providers, increased participation in self-management of disease, and an improved knowledge of their medical conditions .
In patients with PAH, daily activity level, as measured using a physical activity monitor for seven consecutive days, correlated with 6-minute walk distance (6MWD).
The monitor used in the aforementioned PAH study was positioned on the patients' right upper arm with an armband, as opposed to the more popular and more comfortable wristbands used today, such as the Fitbit Flex.
Although the aforementioned PAH study did show a correlation between activity level monitoring and 6MWD, the patients were monitored for only seven days.
It is still unknown whether this correlation would exist over a longer trial period and whether patients, their caregivers, and clinicians would find activity level monitoring useful in helping manage PH.
Studietype
Observasjonsmessig
Registrering (Faktiske)
35
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Multiple Locations, Canada
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Canadian patients are eligible for the study if they have been diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and are stable on optimal medical therapy and who meet the study's eligibility criteria
Beskrivelse
Inclusion Criteria:
- Male or female patients with a diagnosis of Pulmonary Arterial Hypertension (PAH); or inoperable, persistent or recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH),
- Age ≥ 18 years,
- Baseline 6 Minute Walk Distance (6MWD) a minimum of 250 meters or maximum 450 meters, (ensure significant Pulmonary Hypertension(PH) without limiting their participation in the trial)
- WHO Functional Class II or III,
Clinically stable patient defined as within the last 12 months (minimum of 3 months) prior to enrollment, there was no:
- decline in World Health Organization (WHO) Function class or,
- decline in 6MWD by 15% or,
- change of oral PAH/CTEPH therapy (may have flexible diuretics/anticoagulation) or,
- Introduction of parenteral Prostacyclin Analog (PCA) treatment.
- Patients provide written informed consent, are able to understand and follow instructions.
Exclusion Criteria:
- Hypersensitivity to nickel (present in the clasp of the FitBit Flex's band),
- Medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,
- Enrolled in pulmonary rehabilitation program within last 6 months,
- Participating in an interventional study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Patients with PAH and CTEPH
Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
6-minute walk distance (6MWD)
Tidsramme: At baseline
|
(performed by investigator)
|
At baseline
|
|
6-minute walk distance (6MWD)
Tidsramme: At 3 months
|
(performed by investigator)
|
At 3 months
|
|
6-minute walk distance (6MWD)
Tidsramme: At 6 months
|
(performed by investigator)
|
At 6 months
|
|
Number of steps per day
Tidsramme: At baseline
|
(monitored by Fitbit Flex)
|
At baseline
|
|
Number of steps per day
Tidsramme: At 3 months
|
(monitored by Fitbit Flex)
|
At 3 months
|
|
Number of steps per day
Tidsramme: At 6 months
|
(monitored by Fitbit Flex)
|
At 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in quality of life recorded by patient questionnaire Living with Pulmonary hypertension Questionnaire (LPH)
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in compliance with medication using the Moriky´s Questionnaire
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWD
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Change in Borg Dyspnea value recorded by investigator in conjunction with the 6MWD
Tidsramme: At baseline, 3 months and 6 months
|
At baseline, 3 months and 6 months
|
|
Healthcare provider Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
|
Caregiver Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
|
Patient Satisfaction and Usability questionnaire
Tidsramme: At 3 months and 6 months
|
At 3 months and 6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
30. juni 2015
Primær fullføring (Faktiske)
25. november 2016
Studiet fullført (Faktiske)
21. desember 2016
Datoer for studieregistrering
Først innsendt
10. august 2015
Først innsendt som oppfylte QC-kriteriene
31. august 2015
Først lagt ut (Anslag)
1. september 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. desember 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
19. desember 2017
Sist bekreftet
1. desember 2017
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 17926
- DBOX 2014/00466 (Annen identifikator: Company internal)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .